Elegen and GSK entered a collaboration and licensing agreement for the use of Elegen’s cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.   The terms of the agreement include upfront fees and purchase commitments of Elegen’s ENFINIA DNA to support GSK’s development of medicines and vaccines, including RNA vaccines. Elegen is also eligible to receive milestone payments relating to the development of new product features and a potential equity investment i...